Trial Profile
Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibitor (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Locally Advanced, or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2024 Planned End Date changed from 31 Jan 2025 to 31 Jan 2026.
- 06 Mar 2024 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2025.
- 05 Jan 2023 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.